A Phase 2 Study to Compare the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 2 Dose Regimens of IW-1973 in Patients With Stable Type 2 Diabetes and Hypertension
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Praliciguat (Primary)
- Indications Hypertension; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Ironwood Pharmaceuticals
- 19 Dec 2019 Results published in the Diabetologia.
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association